LIPOOTCPharmaceutical PreparationsFiscal year ends December 31

LIPELLA PHARMACEUTICALS INC.

Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025

$0.00+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $2.27K
P/E (TTM): –
Dividend yield: –

LIPELLA PHARMACEUTICALS INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	0.54	0.45	0.18	0.26
Research & Development	3.61	3.04	2.55	1.46
General & Administrative	2.00	2.16	0.23	0.72
Operating Income	-5.08	-4.75	-2.59	-1.92
Interest Expense	–	0.01	0.01	0.01
Interest & Investment Income	0.06	0.14	0.00	0.00
Other Non-Operating Income	0.06	0.13	-0.01	0.05
Pretax Income	-5.02	-4.62	-2.60	-1.87
Net Income	-5.02	-4.62	-2.60	-1.87
EPS (Basic)(per share)	-4.79	-6.16	-5.12	-4.40
EPS (Diluted)(per share)	-4.79	-6.16	-5.12	-4.40
Shares Outstanding (Basic, Weighted)(shares)	1.05	0.75	0.51	0.43
Shares Outstanding (Diluted, Weighted)(shares)	1.05	0.75	0.51	0.43
EBITDA	-5.08	-4.74	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2025

Profitability, TTM

Gross margin: –
Operating margin: -1387.9%
Net margin: -1367.4%
Return on equity, FY2024: -198.1%

Financial strength

Current ratio: 3.24
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 288.9%

Valuation

P/E ratio: –
Price to sales: 0.01
Price to book: 0.00
Dividend yield: –